Neurokinin receptor antagonists

Bibliography

• SEWARD EM, SWAIN CJ: Neurokinin receptor antago-nists. Exp. Opin. Ther. Patents (1999) 9(5):571–582.
   Web of Science ®Google Scholar
• •A very good recent review.
   Google Scholar
• SWAIN C, RUPNIAK NMJ: Progress in the development of neurokinin antagonists. Ann. Rep. Med. Chem. (1999) 34:51-60. A good, concise update of last year's developments.
   Google Scholar
• GAO Z, PEET NP: Recent advances in neurokinin receptor antagonists. Curr. Med. Chem. (1999) 6:375–388.
   PubMed Web of Science ®Google Scholar
• SARIA A: The tachykinin NK3 receptor in the brain: pharmacology and putative functions. Eur. J. Pharmacol (1999) 375:51–60.
   PubMed Web of Science ®Google Scholar
• ••A very good recent review for NKir antagonists in the brain.
   Google Scholar
• SWAIN CJ: Neurokinin receptor antagonists. Prog. Med. Chem. (1998) 35:57–81.
   PubMedGoogle Scholar
• LONGMORE J, HILL RG, HARGREAVES RJ: Neurokinin-receptor antagonists: pharmacological tools and therapeutic drugs. Can. J. Physiol. Pharmacol (1997) 75:612–621.
   PubMed Web of Science ®Google Scholar
• GERSPACHER M, VON SPRECHER A: Dual neurokinin NK1/NK2 receptor antagonists. Drugs Fut. (1999) 24(8)883–892.
   Google Scholar
• ••A good recent review.
   Google Scholar
• MATUSZEK MA, COMIS A, BURCHER E: Binding and functional potency of neurokinin A analogues in the rat ftmdus: a structure-activity study. Pharmacology (1999) 58:227–235.
   PubMed Web of Science ®Google Scholar
• QUARTARA L, MAGGI CA: The tachykinin NK3 receptor: Part II. Distribution and pathophysiological roles. Neuropeptides (1998) 32:1–49.
   PubMed Web of Science ®Google Scholar
• CATHIENI MM, TABAN CH, SORS P, MASTRANGELO D: Binding of gold-protein ligand complexes to neurokinin receptors. Visualization with the electron microscope on pig coronary artery and rat portal vein. Vasc. Res. (1999) 36:59–67.
   Google Scholar
• JENKINSON KM, SOUTHWELL BR, FURNESS JB: Two affinities for a single antagonist at the neuronal NKi tachykinin receptor: evidence from quantitation of receptor endocytosis. Br. J. Pharmacol. (1999) 126(1):131–136.
   PubMed Web of Science ®Google Scholar
• SNIDER RM, CONSTANTINE JW, LOWE III JA et al.: A potent nonpeptide antagonist of the substance P (NKO receptor. Science (1991) 251:435–437.
   Google Scholar
• DESAI MC, LEFKOWITZ SL, THADEIO PF, LONGO KP, SNIDER RM: Discovery of a potent substance P antago-nist: recognition of a key molecular determinant. J. Med. Chem. (1992) 35:4911–4913.
   PubMed Web of Science ®Google Scholar
• SORBERA LA, SILVESTRE J, CASTANER J: GR-205171. Drugs Fut. (1999) 24(3):254–260.
   Google Scholar
• PALMA C, NARDELLI F, MANZINI S: Correlation betweenbinding characteristics and functional antagonism in human glioma cells by tachykinin NKi receptor antagonists. Eur. J. Pharmacol (1999) 374:435–443.
   PubMed Web of Science ®Google Scholar
• DONNELLY D, MAUDSLEY S, GENT JP, MOSER RN, HURRELL CR, FINDLAY JBC: Conserved polar residues in the transmembrane domain of the human tachykinin NK2 receptor: functional roles and structural implica-tions. Biochem. J. (1999) 339:55–61.
   PubMed Web of Science ®Google Scholar
• RENZETTI AR, CATALIOTO RM, CRISCUOLI M et al.:Relevance of aromatic residues in transmembrane segments V to VII for binding of peptide and nonpep-tide antagonists to the human tachykinin NK2 receptor. J. Pharmacol. Exp. Ther. (1999) 290:487–495.
   PubMed Web of Science ®Google Scholar
• RENZETTI AR, CATALIOTO RM, CARLONI C et al. Effects of tyrosine289phenylalanine mutation on binding and functional properties of the human tachykinin NK2 receptor stably expressed in chinese hamster ovary cells. Biochem. Pharmacol (1999) 57:899–906.
   PubMed Web of Science ®Google Scholar
• EMONDS-ALT X, VILAIN P, GOULAOUIC P et al: A potent and selective non-peptide antagonist of the neurokinin A (NK2) receptor. Life Sci. (1992) 50:PL101-PL106.
   Google Scholar
• MILEUSNIC D, LEE JM, MAGNUSON DJ et al.: Neurokinin-3 receptor distribution in rat and human brain: an immunohistochemical study. Neuroscience (1999) 89(4):1269–1290.
   PubMed Web of Science ®Google Scholar
• ••A good, comprehensive comparison on NK3 receptorlocalisation in both species.
   Google Scholar
• EMONDS-ALT X, BICHON D, DUCOUX JP et al.: SR 142801, the first potent non-peptide antagonist of the tachykinin NK3 receptor. Life Sci. (1995) 56:PL27-PL32.
   Google Scholar
• GIARDINA GAM, RAVEGLIA LF, GRUGNI M et al.: Discovery of a novel class of selective non-peptide antagonists for the human neurokinin-3 receptor.2. Identification of (S)-N-(1-Phenylpropy0-3-hydroxy-2--phenylquinoline-4-carboxamide (SB 223412). J. Med. Chem. (1999) 42:1053–1065.
   Google Scholar
• GIARDINA GAM, ARTICO M, CAVAGNERA S et al.: Replacement of the quinoline system in 2-pheny1-4-quinolinecarboxamide NK-3 receptor antagonists. II Pharmaco (1999) 54:364–374.
   Google Scholar
• RUPNIAK NMJ, TATTERSALL FD, WILLIAMS AR et al.: Invitro and in vivo predictors of the anti-emetic activity of tachykinin NK3 receptor antagonists. Eur. J. Pharmacol (1997) 326:201–209.
   PubMed Web of Science ®Google Scholar
• ROBICHAUD A, TATTERSALL FD, CHOUDHURY I, RODGER IW: Emesis induced by inhibitors of Type IV cyclic nucleotide phosphodiesterase (PDE IV) in the ferret. Neuropharmacology (1999) 38:289–297.
   PubMed Web of Science ®Google Scholar
• HESKETH PJ, GRALLA RJ, WEBB W et al.: Randomized Phase II study of the neurokinin 1 receptor antagonist CJ-11,974 in the control of cisplatin-induced emesis. Clin. Oncol. (1999) 17(1)338–343.
   Google Scholar
• NAVARI RM, REINHARDT RR, GRALLA RJ et al.: Reduction of cisplatin-induced emesis by a selective neurokinin-1 receptor antagonist. N Engli Med (1999) 340(3):190–195.
   PubMed Web of Science ®Google Scholar
• ROILA F, BALLATORI E, DEL FAVERO A: Prevention ofcisplatin-induced emesis by a selective neurokinin-1 receptor antagonist. N. Engl. J. Med. (1999) 340(24)1926–1928.
   Google Scholar
• DIEMUNSCH P, SCHOEFFLER P, BRYSSINE B et al.: Antiemetic activity of the NK3 receptor antagonist GR205171 in the treatment of established postopera-tive nausea and vomiting after major gynaecological surgery. Br. J. AnaesL (1999) 82(2):274–276.
   PubMed Web of Science ®Google Scholar
• GESZTESI ZS, SONG D, WHITE PF: Comparison of a new NK-1 antagonist (CP-122,721) to ondansetron in the prevention of post-operative nausea and vomiting. Anesth. Anal. (1998) 86:S32.
   Google Scholar
• FUKUDA H, NAKAMURA E, KOGA T, FURUKAWA N, SHIROSHITA Y: The site of anti-emetic action of tachykinin NK1 receptor antagonists may exist in the modullary area adjacent to the semicompact part of the nucleus ambiguus. Brain Res. (1999) 818:439–449.
   PubMed Web of Science ®Google Scholar
• KRAMER MS, CUTLER N, FEIGHNER J et al.: Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science (1998) 281:1640–1645.
   PubMed Web of Science ®Google Scholar
• RIBEIRO SJ, TEIXEIRA RM, CALIXTO JB, DE LIMA TCM: Tachykinin NK3 receptor involvement in anxiety. Neuropeptides (1999) 33(2):181–188.
   PubMed Web of Science ®Google Scholar
• FURST S: Transmitters involved in antinociception in the spinal cord. Brain Res. Bull. (1999) 48 (2):129–141.
   PubMed Web of Science ®Google Scholar
• DIONNE RA, MAX MB, PARADA S, GORDON SM, MACLEAN DB: Evaluation of a neurokinin-1 antagonist, CP-99,994, in comparison to ibuprofen and placebo in the oral surgery model. Clin. Pharmacol. Ther. (1996) 59(2):216.
   Google Scholar
• REINHARDT RR, LAUB JB, FRICKE JR, POLIS AB, GERTZ BJ: Comparison of a neurokinin-1 antagonist, L-754,030, to placebo, acetominophen and ibuprofen in the dental pain model. Clin. Pharmacol. Ther. (1998) 63:PI-P124.
   Google Scholar
• DE FELIPE C, HERRERO JF, O'BRIEN JA et al.: Altered nociception, analgesia and aggression in mice lacking the receptor for substance P. Nature (1998) 392:394–397.
   Google Scholar
• GOLDSTEIN DJ, WANG O, SAPER JR, STOLTZ R, SILBER-STEIN SD, MATHEW NT: Ineffectivemess of neurokinin-1 antagonist in acute migraine: a crossover study. Cephalagia (1997) 17(7):785–790.
   PubMed Web of Science ®Google Scholar
• NORMAN B, PANEBIANCO D, BLOCK GA: A placebo-controlled, in-clinic study to explore the preliminary safety and efficacy of intraveinous L-758,298 (a prodrug of the NK1 receptor antagonist L-754,030) in the acute treatment of migraine. Cephalagia (1998) 18:407–442.
   Google Scholar
• ANDERSON JJ, RANDALL S, CHASE TN: The neurokinin 1receptor antagonist CP-99,994 reduces catalepsy produced by the dopamine D2 receptor antagonist Raclopride: correlation with extracellular acetylcho-line levels in stratium. J. Pharmacol. Exp. Ther. (1995) 274:928–936.
   PubMed Web of Science ®Google Scholar
• GUEUDET C, SANTUCCI V, SOUBRIE P, LE FUR G: Blockade of neurokinin3 receptors antagonizes drug-induced population response and depolarization block of midbrain dopamine neurons in guinea pigs. Synapse (1999) 33:71–79.
   PubMed Web of Science ®Google Scholar
• GEPPETTI P, TOGNETTO M, TREVISANI M, AMADESI S, BERTRAND C: Tachykinins and kinins in airway allergy. Exp. Opin. Invest. Drugs (1999) 8(7):947–956.
   PubMedGoogle Scholar
• RIZZO CA, VALENTINE AF, EGAN RW KREUTNER W, HEY JA: NK2-receptor mediated contraction in monkey, guinea-pig and human airway smooth muscle. Neuropeptides (1999) 33(1):27–34.
   PubMed Web of Science ®Google Scholar
• SCHUILING M, ZUIDHOF AB, ZAAGSMA J, MEURS H: Role of tachykinin NK1 and NK2 receptors in allergen-induced early and late asthmatic reactions, airway hyperresponsiveness and airway inflammation in conscious, unrestrained guinea pigs. Clin. Exp. Allergy (1999) 29 (Suppl. 2):48–52.
   Google Scholar
• DE VRIES A, DESSING MC, ENGELS F, HENRICKS PA,NIJKAMP FP: Nerve growth factor induces a neurokinin-1 receptor-mediated aiway hyperrespon-siveness in guinea pigs. Am. J. Grit. Care Med. (1999) 159:1541–1544.
   PubMed Web of Science ®Google Scholar
• FAHY JV, WONG HH, GEPPETTI P et al: Effect of an NK1receptor antagonist (CP-99,994) on hypertonic saline-induced bronchoconstriction and cough in male asthmatic subjects. Am. J. Resp. Grit. Care Med. (1995) 152:879–884.
   PubMed Web of Science ®Google Scholar
• ICHINOSE M, MIURA M, YAMAUCHI H et al.: A neurokinin 1-receptor antagonist improves exercise-induced airway narrowing in asthmatic patients. Am. J. Resp. Grit. Care Med. (1996) 153:936–941.
   PubMed Web of Science ®Google Scholar
• VAN SCHOOR J, JOOS GF, CHASSON BL, BROUARD RJ,PAUWELS RA: The effect of the NK2 tachykinin receptor antagonist SR 48968 (saredutant) on neurokinin A-induced bronchoconstriction in asthmatics. Eur. Resp. 1 (1998) 12:17-23.
   Google Scholar
• RICCIARDOLO FLM, RADO V, FABBRI LM, STERK PJ, DIMARIA GU, GEPPETTI P: Bronchoconstriction induced by citric acid inhalation in guinea pigs. Role of tachyki-nins, bradikinin and nitric oxide. Am. J. Resp. Grit. Care (1999) 159:557–562.
   Google Scholar
• JOOS GF, VAN SCHOOR J, KIPS JC, PAUWELS RA: Theeffect of inhaled FK224, a tachykinin NK1 and NK2 receptor antagonist, on neurokinin-A-induced bronchoconstriction in asthmatics. Am. J. Resp. Grit. Care Med. (1996) 153:1781–1784.
   PubMed Web of Science ®Google Scholar
• ADVENIER C, DAOUI S, CUT YY, LAGENTE V, EDMONS-ALT X: Inhibition by the tachykinin NK3 antagonist SR 142801, of substance P-induced microvascular leakage hypersensitivity and airway hyperresponsiveness in guinea pigs. Am. J. Resp. Crit. Care (1996) 153:A163.
   PubMedGoogle Scholar
• LECCI A, TRAMONTANA M, GIULIANI S, MAGGI CA: Role of tachykinin NK1 and NK2 receptors on colonic motility in anesthetized rats: effect of agonists. Can. J. Physiol. Pharmacol (1997) 75(6):582–586.
   PubMed Web of Science ®Google Scholar
• BARTHO L, LENARD L JR, PATACCHINI R et al.: Tachyki-nin receptors are involved in the 'local efferent' motor response to capsaicin in the guinea pig small intestine and oesophagus. Neuroscience (1999) 90(1):221–228.
   PubMed Web of Science ®Google Scholar
• BROCCARDO M, IMPROTA G, TABACCO A: Central tachykinin NK3 receptor in the inhibitory action on the rat colonic propulsion of a new tachykinin, PG-KII. Eur. Pharmacol (1999) 376:67–71.
   PubMed Web of Science ®Google Scholar
• CASTAGLIUOLO I, RIEGLER M, PASHA A et al.:Neurokinin-1 (NK-1) receptor is required in Clostridium difficile-induced enteritis. J. Clin. Invest. (1998) 101:1547–1550.
   PubMed Web of Science ®Google Scholar
• CASTAGLIUOLO I, WANG CC, VALENICK L et al.:Neurotensin is a proinflammatory neuropeptide in colonic inflammation. J. Clin. Invest. (1999) 103:843–849.
   PubMed Web of Science ®Google Scholar
• RIEGLER M, CASTAGLIUOLO I, SO PTC et al: Effects of substance P on human colonic mucosa in vitro. Am. J. Physic)]. (1999) 276:G1473–G1483.
   Google Scholar
• CUTRUFO C, EVANGELISTA S, CIRILLO R et al.: Effect of MEN 11467, a new tachykinin NKi receptor antagonist, in acute rectocolitis induced by acetic acid in guinea-pigs. Eur. J. Pharmacol (1999) 374:277–283.
   PubMed Web of Science ®Google Scholar
• CAO T, GERARD N, BRAINS: Use of NKi knockout mice to analyse substance P-induced edema formation. Am. Physiol. (1999) 277:R476–R481.
   Google Scholar
• QUINLAN K, SONG IS, NAIK S et al.: VCAM-1 Expression on human dermal microvascular endothelial cells is directly and specifically up-regulated by substance P.J. Immunol. (1999) 162:1656–1661.
   Google Scholar
• SANTONI G, PERFUMI MC, SPREGHINI E, ROMAGNOLI S, PICCOLI M: Neurokinin type-1 receptor antagonist inhibit enhancement of T cell functions by substance P in normal and neuromanipulated capsaicin-treated rats. J. Neuroimmunol (1999) 93:15–25.
   PubMed Web of Science ®Google Scholar
• SUZUKI R, FURUNO T, MCKAY DM et al.: Direct neurite-mast cell communication in vitro occurs via the neuropeptide substance P. J. Immunol. (1999) 163:2410–2415.
   PubMed Web of Science ®Google Scholar
• OGAWA K, NABE T, YAMAMURA H, KOHNO S: Nanomolar concentrations of neuropeptides induce histamine release from peritoneal mast cells of a substrain of Wistar rats. Eur. J. Pharmacol (1999) 374:285–291.
   PubMed Web of Science ®Google Scholar
• BAE SJ, MATSUNAGA Y, TANAKA Y, KATAYAMA I: Autocrine induction of substance P mRNA and peptide in cultured normal human keratinocytes. Biochem. Biophys. Res. Comm. (1999) 263:327–333.
   PubMed Web of Science ®Google Scholar
• BINDER W, SCOTT C, WALKER J: Involvement of substance P in the anti-inflammatory effect of the peripherally selective kappa-opioid asimadoline and the NKi antagonist GR205171. Eur. J. Neurosci. (1999) 11:2065–2072.
   PubMed Web of Science ®Google Scholar
• MATOS I, TEIXERIA MM, LEITE R, FREIRE-MAIA L: Pharmacological evidence that neuropeptides mediate part of the actions of scorpion venom on the guinea pig ileum. Eur. J. Pharmacol. (1999) 368:231–236.
   PubMed Web of Science ®Google Scholar
• PALMA C, NARDELLI F, MANZINI S, MAGGI CA: Substance P activates responses correlated with tumor growth in human glioma cell lines bearing tachykinin NK receptors. Br. J. Cancer (1999) 79 (2) :236–243.
   PubMed Web of Science ®Google Scholar